

- **Name:** Hyo Song Kim
- **Current Position & Affiliation:** Associate Professor
Yonsei University College of Medicine
- **Country:** Korea

• **Educational Background:**

2008 Mar - 2013 Feb	PhD, School of Medicine, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic Of, Supervisor(s): Won Ki Kang, MD, PhD
2006 Mar - 2008 Feb	MMS, School of Medicine, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic Of, Supervisor(s): Won Ki Kang, MD, PhD
1996 Mar - 2002 Feb	MD, School of Medicine, Gyeongsang National University, Jinju, Korea

• **Professional Experience:**

2021 Mar – present	Associate Professor, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea, Republic Of
2017 Mar – 2021. Feb	Assistant Professor, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea, Republic Of
2010 Mar – 2017 Feb	Clinical Assistant Professor, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea, Republic Of

Personalizing treatment with translation oncology has been the primary research goal and in view of my extensive experience in translational research using next generation sequencing technology based on prospective clinical trial. The goal of the research is to understand how tumor respond to target agents, characterize mechanism of resistance, and identify potential novel target based on integrated genome-clinical data.

• **Professional Organizations:**

2009 May - present Active member, American Society of Clinical Oncology
2009 May - present Active member, American Association of Cancer Research
2008 Jan - present Active member, Korean Cancer Study Group
2008 Jan - present Active member, Korean Association for Clinical Oncology
2008 Jan - present Active member, Korean Cancer Society

• Main Scientific Publications:

1. Clinical activity of transforming growth factor- β inhibitor vactosertib in combination with imatinib in desmoid tumors: a multicenter phase Ib/II study.
Ahn JH, Lee J, Park C, Beom SH, Kim SH, Lee YH, Yun KH, Kim JE, Baek W, Han YD, Kim SK, Ryu HJ, Jung I, Lee J, Yoon HI, **Kim HS**. Clinical Cancer Research. 2024 Feb 16,
2. Durvalumab plus pazopanib combination in patients with advanced soft tissue sarcomas: a phase II trial.
Cho HJ, Yun KH, Shin SJ, Lee YH, Kim SH, Baek W, Han YD, Kim SK, Ryu HJ, Lee J, Cho I, Go H, Ko J, Jung I, Jeon MK, Rha SY, **Kim HS**. Nature Communications. 2024 Jan 23;15(1):685.
3. Phase II Clinical Trial of Eribulin-Gemcitabine Combination Therapy in Previously Treated Patients With Advanced Liposarcoma or Leiomyosarcoma.
Kim CG, Sim NS, Kim JE, Yun KH, Lee YH, Kim SH, Baek W, Han YD, Kim SK, Kim JH, Koh YW, Jung I, Shin SJ, Rha SY, Ahn JH, **Kim HS**. Clinical Cancer Research. 2022 Aug 2;28(15):3225-3234
4. Therapeutic Implications of TGF- β Pathway in Desmoid Tumor Based on Comprehensive Molecular Profiling and Clinicopathological Properties.
Yun KH, Park C, Ryu HJ, Ock CY, Lee YH, Baek W, Yoon HI, Han YD, Kim SK, Lee J, Kim SJ, Yang KM, Kim SH, **Kim HS**. Cancers (Basel). 2022 Dec 2;14(23):5975
5. Comprehensive Molecular Characterization of Soft Tissue Sarcoma for Prediction of Pazopanib-Based Treatment Response.
Hong JY, Cho HJ, Yun KH, Lee YH, Kim SH, Baek W, Kim SK, Lee Y, Choi YL, Kwon M, Lee J, **Kim HS**. Cancer Research and Treatment. 2023 Apr;55(2):671-683
6. Pemetrexed plus cisplatin in patients with previously treated advanced sarcoma: a multicenter, single-arm, phase II trial.
J. H. Kim, S. H. Kim, M. K. Jeon, J. E. Kim, K. H. Kim, K.-H. Yun, H.-C. Jeung, S. Y. Rha, J.-H. Ahn, and **H.S. Kim** September 02, 2021. ESMO Open